Develops cell therapies for autoimmune diseases and cancer.
Jun 2026Revenue $6.49M/yrExpenses $140M/yr
No trendCash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Fate Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $6.49M and expenses $140M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.65M | $154M | −$148M |
| Dec 2024 | $13.6M | $224M | −$210M |
| Dec 2023 | $63.5M | $254M | −$191M |
| Dec 2022 | $96.3M | $405M | −$308M |
| Dec 2021 | $55.8M | $273M | −$217M |
| Dec 2020 | $31.4M | $160M | −$128M |
| Dec 2019 | $10.7M | $111M | −$101M |
| Dec 2018 | $4.74M | $71.8M | −$67.1M |
| Dec 2017 | $4.11M | $46.2M | −$42.1M |
| Dec 2016 | $4.40M | $36.4M | −$32.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.